Shanghai Haohai Biological Technology Co (SHSE:688366) Beneish M-Score: -2.38 (As of Jun. 26, 2026)


SHSE:688366 Shanghai Haohai Biological Technology Co Ltd SHSE:688366
70 GF Score
Price ¥28.61
GF Value ¥43.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Beneish M-Score?

Shanghai Haohai Biological Technology Co SHSE:688366 -3.57% 70 Beneish M-Score is -2.38 as of Jun. 26, 2026. GuruFocus rates SHSE:688366 with a GF Score™ of 70/100 and a GF Value™ of ¥43.53 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Shanghai Haohai Biological Technology Co ranks better than 50.78% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shanghai Haohai Biological Technology Co's Beneish M-Score or its related term are showing as below:

SHSE:688366' s Beneish M-Score Range Over the Past 10 Years
Min: -2.61   Med: -2.3   Max: -2.06
Current: -2.38

During the past 12 years, the highest Beneish M-Score of Shanghai Haohai Biological Technology Co was -2.06. The lowest was -2.61. And the median was -2.30.


Shanghai Haohai Biological Technology Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Beneish M-Score Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2.11 -2.30 -2.52

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.30 -2.06 -2.08 -2.52 -2.38

SHSE:688366 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Beneish M-Score falls into.


SHSE:688366
70GF Score
Shanghai Haohai Biological Technology Co Ltd SHSE:688366
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shanghai Haohai Biological Technology Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3231+0.528 * 1.0159+0.404 * 1.0178+0.892 * 0.6438+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1343+4.679 * 0.01424-0.327 * 0.9902
=-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Dec24) TTM:
Total Receivables was ¥315 Mil.
Revenue was 571.435 + 547.22 + 606.45 + 0 = ¥1,725 Mil.
Gross Profit was 378.966 + 374.852 + 430.45 + 0 = ¥1,184 Mil.
Total Current Assets was ¥3,390 Mil.
Total Assets was ¥6,666 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,668 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥897 Mil.
Total Current Liabilities was ¥909 Mil.
Long-Term Debt & Capital Lease Obligation was ¥26 Mil.
Net Income was 73.559 + -53.638 + 93.582 + 0 = ¥114 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 18.574 + 0 + 0 + 0 = ¥19 Mil.
Total Receivables was ¥369 Mil.
Revenue was 604.856 + 677.699 + 751.117 + 645.995 = ¥2,680 Mil.
Gross Profit was 407.765 + 477.728 + 536.172 + 447.123 = ¥1,869 Mil.
Total Current Assets was ¥3,658 Mil.
Total Assets was ¥7,121 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,775 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,228 Mil.
Total Current Liabilities was ¥866 Mil.
Long-Term Debt & Capital Lease Obligation was ¥143 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(314.601 / 1725.105) / (369.342 / 2679.667)
=0.182366 / 0.137831
=1.3231

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1868.788 / 2679.667) / (1184.268 / 1725.105)
=0.697396 / 0.68649
=1.0159

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3389.949 + 1667.709) / 6666.309) / (1 - (3658.268 + 1774.767) / 7121.392)
=0.241311 / 0.237082
=1.0178

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1725.105 / 2679.667
=0.6438

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1774.767)) / (0 / (0 + 1667.709))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(896.597 / 1725.105) / (1227.825 / 2679.667)
=0.519735 / 0.458201
=1.1343

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((26.442 + 908.501) / 6666.309) / ((142.744 + 865.893) / 7121.392)
=0.140249 / 0.141635
=0.9902

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(113.503 - 0 - 18.574) / 6666.309
=0.01424

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shanghai Haohai Biological Technology Co has a M-score of -2.44 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.38 mean?
Shanghai Haohai Biological Technology Co (SHSE:688366) has a Beneish M-Score of -2.38 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shanghai Haohai Biological Technology Co and its competitors. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #409 out of 831 companies in the Biotechnology industry, placing it in the top 49.2%.
Is Shanghai Haohai Biological Technology Co's Beneish M-Score too high?
Shanghai Haohai Biological Technology Co's current Beneish M-Score is -2.38. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #409 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #409 out of 831 companies for Beneish M-Score. This puts Shanghai Haohai Biological Technology Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Beneish M-Score is -2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (SHSE:688366) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥43.53, compared to a current price of ¥28.61 — trading 34.3% below its estimated fair value. The current Beneish M-Score is -2.38. Shanghai Haohai Biological Technology Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (SHSE:688366), the current Beneish M-Score is -2.38 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (SHSE:688366) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of ¥28.61 is trading 34.3% below its estimated GF Value™ of ¥43.53. GuruFocus considers Shanghai Haohai Biological Technology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688366:

  • Beneish M-Score: -2.38
  • GF Value™: ¥43.53 vs. price of ¥28.61 (34.3% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688366 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong5HB:Germany
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
70GF Score

Get the complete analysis for SHSE:688366

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥28.61
Price
¥43.53
GF Value